Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 5/20 | 0.58 |
| ▸ | DRD3 | P35462 | 5/20 | 0.58 |
| ▸ | HDAC3 | O15379 | 5/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.52 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.52 |
| ▸ | NCOR2 | Q9Y618 | 4/20 | 0.52 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.52 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.52 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.52 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.52 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.52 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.52 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.52 |
| ▸ | NAMPT | P43490 | 6/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.49 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3084296 | 1.00 | DRD2 (0.58) | DRD2DRD3HDAC3HDAC1HDAC2 | |
| SCHEMBL13276712 | 0.86 | DRD2 (0.61) | DRD2DRD3HDAC3HDAC1HDAC2 | |
| SCHEMBL13276714 | 0.86 | DRD2 (0.61) | DRD2DRD3HDAC3HDAC1HDAC2 | |
| SCHEMBL82726 | 0.85 | DRD2 (0.62) | DRD2DRD3HDAC3HDAC1HDAC2 | |
| SCHEMBL3089088 | 0.85 | DRD2 (0.62) | DRD2DRD3HDAC3HDAC1HDAC2 | |
| SCHEMBL6266296 | 0.80 | DRD3 (0.72) | DRD2DRD3HDAC3HDAC1HDAC2 | |
| SCHEMBL6266293 | 0.80 | DRD3 (0.72) | DRD2DRD3HDAC3HDAC1HDAC2 | |
| SCHEMBL6268825 | 0.80 | DRD3 (0.63) | DRD2DRD3HDAC3HDAC1HDAC2 | |
| SCHEMBL82431 | 0.79 | NAMPT (0.74) | DRD2DRD3HDAC3HDAC1HDAC2 | |
| SCHEMBL3079779 | 0.79 | DRD3 (0.62) | DRD2DRD3HDAC3HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100227896-A1 | USE OF VITAMIN PP COMPOUNDS | ASTELLAS DEUTSCHLAND GMBH (DE) | 2010-09-09 | — | — | US | claimed |
| EP-1044197-B1 | PIPERIDINYL-SUBSTITUTED PYRIDYLALKANE, ALKENE AND ALKYNE CARBOXAMIDES AS CYTOSTATIC AGENTS AND IMMUNOSUPPRESSANTS | ASTELLAS PHARMA GMBH (DE) | 2006-04-19 | — | — | EP | claimed |
| EP-1079832-B1 | USE OF VITAMIN PP COMPOUNDS | KLINGE CO CHEM PHARM FAB (DE) | 2005-11-30 | — | — | EP | claimed |
| US-6593344-B1 | These substances have especially high cytostatic activities and pronounced immunosuppressive properties which make them suitable for therapeutic treatment in broad tumor spectrum and autoimmune diseases | KLINGE PHARMA GMBH (DE) | 2003-07-15 | — | — | US | claimed |
| US-20100227896-A1 | USE OF VITAMIN PP COMPOUNDS | ASTELLAS DEUTSCHLAND GMBH (DE) | 2010-09-09 | — | — | US | disclosed |
| EP-1044197-B1 | PIPERIDINYL-SUBSTITUTED PYRIDYLALKANE, ALKENE AND ALKYNE CARBOXAMIDES AS CYTOSTATIC AGENTS AND IMMUNOSUPPRESSANTS | ASTELLAS PHARMA GMBH (DE) | 2006-04-19 | — | — | EP | disclosed |
| EP-1079832-B1 | USE OF VITAMIN PP COMPOUNDS | KLINGE CO CHEM PHARM FAB (DE) | 2005-11-30 | — | — | EP | disclosed |
| US-6593344-B1 | These substances have especially high cytostatic activities and pronounced immunosuppressive properties which make them suitable for therapeutic treatment in broad tumor spectrum and autoimmune diseases | KLINGE PHARMA GMBH (DE) | 2003-07-15 | — | — | US | disclosed |
| EP-1044197-A2 | NEW PIPERIDINYL-SUBSTITUTED PYRIDYLALKANE, ALKENE AND ALKINE CARBOXAMIDES | Klinge Pharma GmbH (DE) | 2000-10-18 | — | — | EP | disclosed |
| WO-1999031060-A2 | PIPERIDINYL-SUBSTITUTED PYRIDYLALKANE, ALKENE AND ALKINE CARBOXAMIDES AS CYTOSTATICS AND IMMUNESUPPRESSANTS | KLINGE PHARMA GMBH (DE) | 1999-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100227896-A1 | USE OF VITAMIN PP COMPOUNDS | PNPO, NAMPT, NAPRT | DRD2 4023/4885DRD3 4289/4885HDAC3 768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.